Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear

Yale Journal of Biology and Medicine

Volumn 84, Issue 4, 2011, Pages 371-380

  Dimberu, Peniel M ^a   Leonhardt, Ralf M ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer vaccine; Immune response; Immunotherapy; Monoclonal antibody

Indexed keywords

BETA 2 MICROGLOBULIN; BEVACIZUMAB; CANCER VACCINE; CETUXIMAB; DNA VACCINE; G 2092M; GAMMA INTERFERON; GLYCOPROTEIN GP 100; HEPATITIS B VACCINE; HLA ANTIGEN; IBRITUMOMAB TIUXETAN; INTERLEUKIN 2; IPILIMUMAB; LYMPHOMA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NATURAL KILLER CELL RECEPTOR; PLACEBO; RITUXIMAB; SIPULEUCEL T; TAPASIN; TOSITUMOMAB I 131; TRANSFORMING GROWTH FACTOR BETA; TRASTUZUMAB; TUMOR ANTIGEN; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ADOPTIVE TRANSFER; ANTIGEN PRESENTATION; APOPTOSIS; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; COLORECTAL CANCER; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; GLIOBLASTOMA; HAPLOTYPE; HEMATOLOGIC MALIGNANCY; HEPATITIS B; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; LIGAND BINDING; LIVER CELL CARCINOMA; LYMPHOMA; MELANOMA; NATURAL KILLER CELL; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PAPILLOMAVIRUS INFECTION; PHARMACOLOGICAL BLOCKING; PROSTATE CANCER; PROTEIN EXPRESSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTE COUNT; TUMOR IMMUNITY; UPREGULATION;

ANIMALS; ANTIGEN PRESENTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNE EVASION; IMMUNE SYSTEM; IMMUNOTHERAPY; NEOPLASMS;

EID: 84856342711     PISSN: 00440086     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (52)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-36.
3. Urruticoechea A, Alemany R, Balart J, Villanueva A, Vinals F, Capella G. Recent advances in cancer therapy: an overview. Curr Pharm Des. 2010;16(1):3-10.
4. Davis ID. An overview of cancer immunotherapy. Immunol Cell Biol. 2000;78(3):179-95.
5. Moore N, Lyle S. Quiescent, slow-cycling stem cell populations in cancer: a review of the evidence and discussion of significance. J Oncol. Epub 2010 Sep 29.
6. Li CY, Huang Q, Kung HF. Cytokine and immuno-gene therapy for solid tumors. Cell Mol Immunol. 2005;2(2):81-91.
7. Bakacs T, Mehrishi JN, Moss RW. Ipilimumab (Yervoy) and the TGN1412 catastrophe. Immunobiology. Epub 2011 Jul 7.
8. Fang L, Lonsdorf AS, Hwang ST. Immunotherapy for advanced melanoma. J Invest Dermatol. 2008;128 (11):2596-605.
9. Harris AL, Hochhauser D. Mechanisms of multidrug resistance in cancer treatment. Acta Oncol. 1992;31(2):205-13.
10. Rufer E, Leonhardt RM, Knittler MR. Molecular architecture of the TAP-associated MHC class I peptide-loading complex. J Immunol. 2007;179(9):5717-27.
11. Leonhardt RM, Fiegl D, Rufer E, Karger A, Bettin B, Knittler MR. Post-endoplasmic reticulum rescue of unstable MHC class I requires proprotein convertase PC7. J Immunol. 2010;184(6):2985-98.
12. Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu Rev Immunol. 1994;12:181-207.
13. Chavez-Galan L, Arenas-Del Angel MC, Zenteno E, Chavez R, Lascurain R. Cell death mechanisms induced by cytotoxic lymphocytes. Cell Mol Immunol. 2009;6(1):15-25.
14. Vigneron N, Van den Eynde BJ. Insights into the processing of MHC class I ligands gained from the study of human tumor epitopes. Cell Mol Life Sci. 2011;68(9):1503-20.
15. Grizzi F, Franceschini B, Hamrick C, Frezza EE, Cobos E, Chiriva-Internati M. Usefulness of cancer-testis antigens as biomarkers for the diagnosis and treatment of hepatocellular carcinoma. J Transl Med. 2007;5:3.
16. Romero JM, Jimenez P, Cabrera T, Cozar JM, Pedrinaci S, Tallada M, et al. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLAABC loss in bladder cancer. Int J Cancer. 2005;113(4):605-10.
17. Garrido F, Cabrera T, Aptsiauri N. "Hard" and "soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int J Cancer. 2010;127(2):249-56.
18. Wischhusen J, Friese MA, Mittelbronn M, Meyermann R, Weller M. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo. J Neuropathol Exp Neurol. 2005;64(6):523-8.
19. Groth A, Kloss S, Pogge von Strandmann E, Koehl U, Koch J. Mechanisms of tumor and viral immune escape from natural killer cellmediated surveillance. J Innate Immun. 2011;3(4):344-54.
20. Adler AJ. Mechanisms of T cell tolerance and suppression in cancer mediated by tumor-associated antigens and hormones. Curr Cancer Drug Targets. 2007;7(1):3-14.
21. Uyttenhove C, Pilotte L, Theate I, Stroobant V, Colau D, Parmentier N, et al. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat Med. 2003;9(10):1269-74.
22. Della Chiesa M, Carlomagno S, Frumento G, Balsamo M, Cantoni C, Conte R, et al. The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46-and NKG2D-activating receptors and regulates NK-cell function. Blood. 2006;108(13):4118-25.
23. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol. 2010;74(1):27-39.
24. Smith FO, Downey SG, Klapper JA, Yang JC, Sherry RM, Royal RE, et al. Treatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccines. Clin Cancer Res. 2008;14(17):5610-8.
25. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011;364(22):2119-27.
26. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-9.
27. Goff SL, Smith FO, Klapper JA, Sherry R, Wunderlich JR, Steinberg SM, et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J Immunother. 2010;33(8):840-7.
28. Bour-Jordan H, Esensten JH, Martinez-Llordella M, Penaranda C, Stumpf M, Bluestone JA. Intrinsic and extrinsic control of peripheral T-cell tolerance by costimulatory molecules of the CD28/ B7 family. Immunol Rev. 2011;241(1):180-205.
29. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-23.
30. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-26.
31. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, et al. The combination of ipilimumab and IL-2 appears to have an increased complete response rate. J Clin Oncol. 2010;28(15 Suppl): 8544.
32. Sznol M, Powderly JD, Smith DC, Brahmer JR, Drake CG, McDermott DF, et al. Safety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies. J Clin Oncol. 2010;28(15 Suppl):2506.
33. Chang MH, You SL, Chen CJ, Liu CJ, Lee CM, Lin SM, et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst. 2009;101(19):1348-55.
34. Lowy DR, Schiller JT. Prophylactic human papillomavirus vaccines. J Clin Invest. 2006;116(5):1167-73.
35. Frazer IH, Lowy DR, Schiller JT. Prevention of cancer through immunization: Prospects and challenges for the 21st century. Eur J Immunol. 2007;37(Suppl 1):S148-55.
36. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411-22.
37. Schuster SJ, Neelapu SS, Gause BL, Muggia FM, Gockerman JP, Sotomayor EM, et al. Idiotype vaccine therapy (BiovaxID) in follicular lymphoma in first complete remission: Phase III clinical trial results. J Clin Oncol. 2009;27:2A.
38. Jacobi AM, Dorner T. Current aspects of anti-CD20 therapy in rheumatoid arthritis. Curr Opin Pharmacol. 2010;10(3):316-21.
39. Lanini S, Molloy AC, Fine PE, Prentice AG, Ippolito G, Kibbler CC. Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis. BMC Med. 2011;9:36.
40. Stern M, Herrmann R. Overview of monoclonal antibodies in cancer therapy: present and promise. Crit Rev Oncol Hematol. 2005;54(1):11-29.
41. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001;344(11):783-92.
42. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350(23):2335-42.
43. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70(10):779-87.
44. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005;16(1):102-8.
45. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8):3992-5.
46. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21-8.
47. Waldmann TA. Immunotherapy: past, present and future. Nat Med. 2003;9(3):269-77.
48. Milenic DE, Brady ED, Brechbiel MW. Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov. 2004;3(6):488-99.
49. Jacene HA, Filice R, Kasecamp W, Wahl RL. Comparison of 90Y-ibritumomab tiuxetan and 131I-tositumomab in clinical practice. J Nucl Med. 2007;48(11):1767-76.
50. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003;348(11):994-1004.
51. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-16.
52. De Clercq E. Antiretroviral drugs. Curr Opin Pharmacol. 2010;10(5):507-15.